Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Washington for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Washington only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Washington (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Elizabeth Gunderson (NPI 1053401745)

Field	Value
Entity Type	Individual
Organization	Elizabeth Gunderson
Address	1204 N Vercler Rd
City	Spokane Valley
State	WA
ZIP	99216
Taxonomy	Medical Oncology Physician
NPI Enumerated	October 13, 2006

Payer Source	Total Paid
Medicare	$1.6M
Medicaid	$0

Key Findings

Provider profile and tenure: ELIZABETH GUNDERSON is a Medical Oncology Physician based in SPOKANE VALLEY, WA with an NPI enumerated on 2006-10-13 (~20 years ago). The provider’s lifetime Medicare revenue on file is $1.6M and there is no Medicaid billing on file, indicating a long-tenured clinician whose observable payer footprint is effectively single-payer Medicare.

Revenue concentration: this provider’s top 3 Medicare codes account for 82.8% of total Medicare revenue, driven primarily by J9299, J9271, and J0897. Those codes generate $610.1K (37.8%), $507.4K (31.4%), and $220.3K (13.6%) respectively, showing an extreme concentration of Medicare dollars in a very small set of high-impact drug codes.

Business/service-line implication: the dominant codes J9299 and J9271 are nivolumab and pembrolizumab (immuno-oncology agents) billed per mg (25.4K claims at $24 avg paid/claim for J9299 and 11.8K claims at $43 avg paid/claim for J9271), with J0897 (denosumab) providing supportive bone-targeted therapy (12.2K claims at $18 avg paid/claim). This mix indicates the practice operates primarily as an oncology infusion/service line focused on high-volume, per-milligram biologic administration rather than solely fee-for-service office consults.

Clinical service mix and administration activity: chemotherapy administration codes appear in the top codes (96413 with 472 claims, $49.6K revenue and 96417 with 175 claims, $9.1K revenue), showing the provider also delivers procedural infusion services in addition to high-cost immunotherapies. These administration codes rank around the upper national percentiles (96413 rank #792 of 7514, 89th percentile; 96417 rank #326 of 3014, 89th percentile), consistent with a clinic that combines drug administration with on-site infusion operations.

E/M utilization is unusually high relative to peers: 99215 accounts for 610 claims and $82.4K (5.1% of Medicare revenue) and is flagged as an "extreme outlier" (rank #1157 of 145531 providers, 99th percentile). This suggests a high volume of complex, high-level evaluation and management visits in the record, which may reflect a clinically complex patient panel or differences in visit mix and documentation intensity compared with national peers.

Competitive standing on top drug codes: the provider’s national ranks show mixed positioning—J9299 ranks #102 of 505 (80th percentile; typical), J9271 ranks #965 of 1841 (48th percentile; typical), and J0897 ranks #801 of 10057 (92th percentile; typical). In plain terms, this clinician is a meaningful national participant for nivolumab and especially for denosumab by volume, while pembrolizumab activity is closer to the mid-distribution among peers.

Payer mix and risk exposure: there is no Medicaid billing on file ("none below"), so the provider’s recorded outpatient revenue exposure rests entirely with Medicare ($1.6M). That single-payer concentration means revenue and utilization patterns observed here are driven by Medicare policies and patient mix, with little to no direct Medicaid exposure or state-level payer influence evident in these data.

Operational implication of unit-based J-code billing: the top revenue drivers are billed per mg and show very large claim volumes with modest average paid per claim (J9299 $24 avg paid/claim for 25.4K claims, J9271 $43 avg paid/claim for 11.8K claims), consistent with high-frequency, weight/volume-based billing typical of biologic infusion practices. For network managers and contracting teams, this pattern signals that managing drug acquisition, reimbursement rates for per-mg J-codes, and infusion reimbursement will be the primary levers affecting this provider’s revenue profile.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

45 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9299	Injection, nivolumab, 1 mg	25,420	$20	$610.1K
J9271	Injection, pembrolizumab, 1 mg	11,800	$40	$507.4K
J0897	Injection, denosumab, 1 mg	12,240	$20	$220.3K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	610	$140	$82.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	470	$110	$49.6K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	12,600	$1	$25.2K
J1439	Injection, ferric carboxymaltose, 1 mg	18,750	$1	$18.8K
J9395	Injection, fulvestrant, 25 mg	1,560	$10	$12.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	110	$90	$10K
96417	In this add–on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report administration of a different chemotherapy…	180	$50	$9.1K

Showing 1–10 of 45

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 45 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Washington Distribution

Elizabeth Gunderson — 7 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Washington

Full comparison — all codes billed, vs. state median

45 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	11	30	9,600	$40	$465.7K
J9299	1	10	17,740	$20	$404.3K
J0897	8	150	1,800	$20	$57.9K
J3490	11	70	70	$50	$51.2K
J0881	6	30	7,810	$1	$19.8K
J1439	2	10	18,000	$1	$15.2K
96413	6	160	80	$110	$15K
J9217	76	80	90	$130	$14.9K
J9395	4	10	1,890	$10	$14.6K
99214	5,044	10,860	100	$80	$13.6K

Showing 1–10 of 45

Related Providers

Other providers that share a Tax Identification Number (TIN) with Elizabeth Gunderson, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Allina Health System	MN	Ambulance	$9M	$118M
Allina Health System	MN	General Acute Care Hospital	$0	$48.8M
Allina Health System	MN	Internal Medicine Physician	$0	$32.9M
Allina Health System	MN	General Acute Care Hospital	$0	$27M
Allina Health System	MN	General Acute Care Hospital	$0	$25.7M
Allina Health System	MN	Family Medicine Physician	$0	$22.2M
Allina Health System	MN	Physical Medicine & Rehabilitation Physician	$0	$18.2M
Allina Health System	MN	Obstetrics & Gynecology Physician	$0	$13.2M
St Francis Regional Medical Center	MN	General Acute Care Hospital	$0	$13M
Allina Health System	MN	Family Medicine Physician	$0	$10.8M

Nearby Providers

Other providers in the same ZIP code as Elizabeth Gunderson, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Providence Health & Services - Washington	WA	Home Infusion Therapy Pharmacy	$27.8K	$41.8M
Incyte Pathology, PLLC	WA	Anatomic Pathology & Clinical Pathology Physician	$0	$27.5M
Multicare Health System	WA	General Acute Care Hospital	$0	$24.7M
Community Health Association Of Spokane	WA	Federally Qualified Health Center (FQHC)	$0	$18.1M
American Behavioral Health Systems, Inc.	WA	Substance Abuse Rehabilitation Facility	$0	$9.5M
Peaks And Plains Medical, Inc.	WA	Durable Medical Equipment & Medical Supplies	$0	$6.4M
Kirk Fuhriman PLLC	WA	Dentist	$0	$5.7M
Community Health Association Of Spokane	WA	Federally Qualified Health Center (FQHC)	$0	$3.4M
Incyte Pathology, PLLC	WA	Clinical Medical Laboratory	$3.2M	$159.4K
Lincare Inc.	WA	Durable Medical Equipment & Medical Supplies	$0	$3.1M

Elizabeth Gunderson — Billing Profile & Reimbursement Data

Sign up for Elizabeth Gunderson — Billing Profile & Reimbursement Data policy alerts

Elizabeth Gunderson — Billing Profile & Reimbursement Data

Sign up for Elizabeth Gunderson — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References